Review
Immunology
Kazumi Nakano, Toshiki Watanabe
Summary: HTLV-1 is an oncovirus that causes ATL and other inflammatory diseases. Most infected individuals maintain a latent state, which may be an intrinsic characteristic acquired during HTLV-1's evolution. We compared the pathological aspects of HTLV-1 and HIV-1 and investigated the importance of viral replication regulators in infected T cells.
FRONTIERS IN IMMUNOLOGY
(2022)
Article
Virology
Kazumi Nakano, Koichi Yokoyama, Shuichi Shin, Koki Uchida, Kazuki Tsuji, Marie Tanaka, Kaoru Uchimaru, Toshiki Watanabe
Summary: The human T-cell leukemia virus type 1 (HTLV-1) integrates into the human genome and utilizes the host T cell gene expression machinery for viral replication. Rex, a viral RNA-binding protein, is responsible for transporting viral mRNAs out of the nucleus to enhance virus particle formation. However, the detailed mechanism of how Rex stabilizes and prevents extra splicing of these viral mRNAs for efficient translation is still unknown. In this study, the researchers analyzed changes in gene expression and splicing patterns in T cells overexpressing Rex. They also identified 81 human proteins interacting with Rex, involved in transcription, splicing, translation, and mRNA quality control. The findings showed that Rex interacts with key proteins involved in transcription and splicing, and its overexpression drastically alters the expression profiles and splicing patterns of various genes. The research sheds light on the molecular mechanism of Rex function and its impact on host cell phenotype.
Article
Virology
Kazumi Nakano, Nobuaki Karasawa, Masaaki Hashizume, Yuetsu Tanaka, Takeo Ohsugi, Kaoru Uchimaru, Toshiki Watanabe
Summary: Studies have shown that the Rex protein of HTLV-1 suppresses the nonsense-mediated mRNA decay (NMD) pathway by binding to host key regulator Upf1 and interacting with SMG5 and SMG7. It also selectively binds to Upf3B, replacing it with a less active form to reduce NMD activity.
Review
Biochemistry & Molecular Biology
Caio Bezerra Machado, Leidivan Sousa da Cunha, Jersey Heitor da Silva Maues, Flavia Melo Cunha de Pinho Pessoa, Marcelo Braga de Oliveira, Rodrigo Monteiro Ribeiro, Germison Silva Lopes, Manoel Odorico de Moraes Filho, Maria Elisabete Amaral de Moraes, Andre Salim Khayat, Caroline Aquino Moreira-Nunes
Summary: This study analyzed the deregulated miRNA expression in HTLV-1 infected cells and patients' samples and identified 12 miRNAs and 90 genes with significant biological interactions that may play a role in the onset of ATL. These miRNAs and genes are associated with key signaling pathways.
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES
(2022)
Review
Immunology
Roberto S. Accolla
Summary: This review discusses the expression of HTLV-1 basic leucine-zipper factor HBZ during HTLV-1 infection, providing a deeper understanding of HTLV-1 infection and oncogenesis mechanisms, and suggesting new directions for further research.
FRONTIERS IN IMMUNOLOGY
(2022)
Review
Oncology
Nicolas Ducasa, Daniel Grasso, Paula Benencio, Daniela L. Papademetrio, Mirna Biglione, Fatah Kashanchi, Carolina Berini, Maria Noe Garcia
Summary: HTLV-1, as the etiological agent of ATLL, interacts with host cells through its viral proteins to promote viral replication and T cell transformation by engaging NF-kappa B and autophagy pathways. Additionally, HTLV-1 utilizes the autophagy pathway to achieve its infective goals.
FRONTIERS IN ONCOLOGY
(2021)
Review
Microbiology
Joshua J. Tu, Victoria Maksimova, Lee Ratner, Amanda R. Panfil
Summary: HTLV-1 is an oncogenic human retrovirus that causes lifelong infection. It can lead to aggressive malignancies or progressive neurodegenerative diseases. Treatment options for HTLV-1-associated diseases are limited and the prognosis for ATL is poor. Early acquisition of the virus increases the risk of disease development. Currently, there is no cure or reliable prevention measure for HTLV-1 infection.
FRONTIERS IN MICROBIOLOGY
(2022)
Article
Biotechnology & Applied Microbiology
Yuji Shimizu, Hirotomo Yamanashi, Jun Miyata, Midori Takada, Yuko Noguchi, Yukiko Honda, Fumiaki Nonaka, Seiko Nakamichi, Yasuhiro Nagata, Takahiro Maeda
Summary: This study found an association between the VEGF polymorphism rs3025039 and HTLV-1 infection, with carriers of the rs3025039 (T) allele having a lower risk of HTLV-1 infection. This suggests that genetic characteristics related to lower angiogenesis activity may be associated with a decreased chance of HTLV-1 infection.
BIOENGINEERING-BASEL
(2022)
Article
Microbiology
Daisuke Kodama, Masakazu Tanaka, Toshio Matsuzaki, Satoshi Nozuma, Eiji Matsuura, Hiroshi Takashima, Shuji Izumo, Ryuji Kubota
Summary: The study compared the performance of different detection methods in the CSF of HAM/TSP patients and HTLV-1 carriers, demonstrating that CLIA was closer to PA in performance, while CLEIA had lower sensitivity.
JOURNAL OF CLINICAL MICROBIOLOGY
(2021)
Article
Public, Environmental & Occupational Health
Yuji Shimizu, Kazuhiko Arima, Yuko Noguchi, Shin-Ya Kawashiri, Hirotomo Yamanashi, Mami Tamai, Yasuhiro Nagata, Takahiro Maeda
Summary: This cross-sectional study found a significant inverse association between HTLV-1 infection and hypertension, particularly in subjects with high platelet levels. However, among non-hypertensive subjects, HTLV-1 infection was significantly positively associated with atherosclerosis in individuals with the highest platelet levels.
ENVIRONMENTAL HEALTH AND PREVENTIVE MEDICINE
(2021)
Review
Immunology
Mohammad Jalili-Nik, Arash Soltani, Baratali Mashkani, Houshang Rafatpanah, Seyed Isaac Hashemy
Summary: Immunotherapy through immune checkpoints blockade has revolutionized the treatment of solid tumors. Blockade of PD-1 and its ligand has shown promising results in clinical studies, with ongoing investigations into the potential therapeutic effects of PD-1 inhibition in ATLL patients.
INTERNATIONAL IMMUNOPHARMACOLOGY
(2021)
Article
Immunology
Julia Dugardin, Magalie Demar, Nezha Hafsi, Hakim Amroun, Jean-Markens Aurelus, Kinan Drak Alsibai, Andre Ntoutoum, Florin Santa, Mathieu Nacher, Nadia Sabbah
Summary: This study investigated the association between HTLV-1 and thyroid dysfunction, and found that the prevalence of thyroid dysfunction in HTLV-1 infected patients was significantly higher than that in the control group.
FRONTIERS IN CELLULAR AND INFECTION MICROBIOLOGY
(2023)
Review
Microbiology
Edward Lin, Amanda R. Panfil, Grace Sandel, Pooja Jain
Summary: The genome of retroviruses contains two promoter elements, LTR, at the 5' and 3' ends. Although the 5' LTR is responsible for gene expression, the 3' LTR also acts as a promoter and produces antisense transcripts. This review focuses on antisense transcription in human retroviruses, specifically discussing the role of MEF-2 transcription factors, the function of antisense protein products, and the therapeutic application in HIV-1 and HTLV-1 co-infection.
FRONTIERS IN MICROBIOLOGY
(2022)
Review
Public, Environmental & Occupational Health
Iris Montano-Castellon, Cleyde Sheyla Chachaqui Marconi, Clara Saffe, Carlos Brites
Summary: This systematic review examined the clinical outcomes in individuals co-infected with HIV-1 and HTLV-1/HTLV-2. The results showed that co-infected patients had shorter survival, higher mortality rate, and faster disease progression compared to those with mono-infections. Additionally, co-infected patients were more likely to have certain diseases and neurological manifestations. The findings highlight the urgent need for prevention, control measures, and comprehensive care for individuals with HIV-1 and HTLV-1/HTLV-2 co-infections.
FRONTIERS IN PUBLIC HEALTH
(2022)
Article
Microbiology
Akihito Koseki, Natsumi Araya, Makoto Yamagishi, Junji Yamauchi, Naoko Yagishita, Naoki Takao, Katsunori Takahashi, Yasuo Kunitomo, Daisuke Honma, Kazushi Araki, Kaoru Uchimaru, Tomoo Sato, Yoshihisa Yamano
Summary: In this study, elevated expression of EZH2 was found in patients with HAM. EZH1/2 selective inhibitors and EZH1/2 inhibitors suppressed the proliferation of HTLV-1-infected cells in HAM by inducing apoptosis and modulating immune response, suggesting the potential of these inhibitors as therapeutic agents for HAM.
FRONTIERS IN MICROBIOLOGY
(2023)
Article
Cell Biology
Micol Silic-Benussi, Gloria Scattolin, Ilaria Cavallari, Sonia Minuzzo, Paola del Bianco, Samuela Francescato, Giuseppe Basso, Stefano Indraccolo, Donna M. D'Agostino, Vincenzo Ciminale
CELL DEATH & DISEASE
(2018)
Review
Microbiology
Donna M. D'Agostino, Ilaria Cavallari, Maria Grazia Romanelli, Vincenzo Ciminale
FRONTIERS IN MICROBIOLOGY
(2019)
Review
Oncology
Ilaria Cavallari, Loredana Urso, Evgeniya Sharova, Giulia Pasello, Vincenzo Ciminale
FRONTIERS IN ONCOLOGY
(2019)
Review
Oncology
Loredana Urso, Ilaria Cavallari, Evgeniya Sharova, Francesco Ciccarese, Giulia Pasello, Vincenzo Ciminale
BRITISH JOURNAL OF CANCER
(2020)
Review
Microbiology
Stefania Fochi, Vincenzo Ciminale, Elisabetta Trabetti, Umberto Bertazzoni, Donna M. D'Agostino, Donato Zipeto, Maria Grazia Romanelli
Review
Virology
Maria Omsland, Micol Silic-Benussi, Ramona Moles, Sarkis Sarkis, Damian F. J. Purcell, David Yurick, Georges Khoury, Donna M. D'Agostino, Vincenzo Ciminale, Genoveffa Franchini
Article
Hematology
Greta Forlani, Mariam Shallak, Alessandra Tedeschi, Ilaria Cavallari, Ambroise Marcais, Olivier Hermine, Roberto S. Accolla
Summary: This study investigates the expression pattern of HBZ protein in patients with Adult T-cell leukemia-lymphoma (ATL). The findings show that HBZ is expressed in both the cytoplasm and nucleus of ATL patient cells, regardless of clinical status, with a strong preference for cytoplasmic localization.
Article
Oncology
Evgeniya Sharova, Marco Maruzzo, Paola Del Bianco, Ilaria Cavallari, Francesco Pierantoni, Umberto Basso, Vincenzo Ciminale, Vittorina Zagonel
Summary: This study investigated the potential of cfmiRNAs as prognostic markers for mCRPC patients treated with ARTA. The results suggest that plasma levels of miR-21-5p, miR-141-3p, miR-223-3p, tCRPC, and Hb levels strongly correlated with PFS and OS. Multivariate analysis revealed that low plasma levels of miR-21, shorter tCRPC, and lower Hb values were independent factors predicting reduced PFS and OS. These findings highlight the potential of cfmiRNA, tCRPC, and Hb as non-invasive tools for prognostic stratification of mCRPC patients receiving ARTA.
FRONTIERS IN ONCOLOGY
(2021)
Article
Oncology
Paola Todeschini, Elisa Salviato, Chiara Romani, Vittoria Raimondi, Francesco Ciccarese, Federico Ferrari, Germana Tognon, Sergio Marchini, Maurizio D'Incalci, Laura Zanotti, Antonella Ravaggi, Franco Odicino, Enrico Sartori, Donna M. D'Agostino, Michele Samaja, Chiara Romualdi, Eliana Bignotti
Summary: In this study, miR-23a-3p was identified as a potential biomarker for chemoresistance and poor prognosis in HGSOC patients, with potential involvement in the platinum resistance pathway targeting APAF-1 gene. Evaluation of miR-23a-3p expression may guide clinical management of platinum-resistant patients, and the miR23a-3p/APAF1 axis could be a target for personalized medicine in HGSOC patients.
Review
Oncology
Ilaria Cavallari, Francesco Ciccarese, Evgeniya Sharova, Loredana Urso, Vittoria Raimondi, Micol Silic-Benussi, Donna M. D'Agostino, Vincenzo Ciminale
Summary: MicroRNAs of the miR-200 family play crucial roles in regulating gene expression in cancer cells, potentially serving as biomarkers for cancer detection. The mature miR-200 family microRNAs are abundantly expressed in epithelial cells, contributing to maintaining the epithelial phenotype and inhibiting cancer development. These microRNAs exhibit both tumor suppressor and pro-metastatic functions, showing promise as biomarkers for epithelial cancers.
Article
Biochemistry & Molecular Biology
Micol Silic-Benussi, Evgeniya Sharova, Alberto Corradin, Loredana Urso, Vittoria Raimondi, Ilaria Cavallari, Barbara Buldini, Samuela Francescato, Sonia A. Minuzzo, Donna M. D'Agostino, Vincenzo Ciminale
Summary: The combination of everolimus and verapamil has been found to enhance the anti-oxidative and cell death effects on T-ALL cells. This combination therapy also showed significant inhibition of tumor growth in refractory T-ALL, providing a potential treatment option for patients who do not respond to standard chemotherapy.
Article
Oncology
Ilaria Cavallari, Angela Grassi, Paola Del Bianco, Alberto Aceti, Carlotta Zaborra, Evgeniya Sharova, Irene Bertazzolo, Donna M. D'Agostino, Massimo Iafrate, Vincenzo Ciminale
